{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T20:04:32Z","timestamp":1792008272137,"version":"4.4.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,8,14]],"date-time":"2020-08-14T00:00:00Z","timestamp":1597363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,8,14]],"date-time":"2020-08-14T00:00:00Z","timestamp":1597363200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Ovarian toxicity is a dreaded complication of cyclophosphamide (CYC). With the use of lower cumulative doses of intravenous CYC (modified NIH regimens) and availability of better markers of ovarian toxicity, the incidence of ovarian dysfunction needs reassessment. Lupus disease activity, by itself, is also believed to affect ovarian function negatively.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This single-centre prospective cohort study recruited 50 female patients of severe lupus aged 18\u201340\u2009years. Twenty-five patients each received induction with either monthly intravenous CYC (0.5\u20130.75\u2009g\/m<jats:sup>2<\/jats:sup>) for 6\u20139\u2009months or daily oral mycophenolate mofetil (MMF). Details of menstrual irregularities; serum levels of FSH, LH, estradiol, AMH, and inhibin B; and sonographic assessment of ovarian volume and antral follicular count were done at baseline and 6\u00a0months after treatment. Amenorrhoeic patients were re-evaluated at 1\u00a0year.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Mean (SD) age of subjects in the CYC and MMF groups was 31.4 (6.3) and 28.4 (4.4) years, respectively. Mean (SD) SLEDAI at the initiation of therapy was 7.2 (2.5) in the CYC group and 5.8 (3.4) in the MMF group. The mean cumulative dose of CYC used was 4.6 (1.8) g. Three patients in the CYC group (versus none in MMF) had amenorrhoea at 6\u00a0months\u2014two of these regained menses within 6\u00a0months, while only one (4%) developed sustained amenorrhoea (lasting more than 12\u2009months) at 41\u2009years of age, likely menopause. Serum FSH levels increased (<jats:italic>p<\/jats:italic>\u2009=\u20090.03), while AMH (<jats:italic>p<\/jats:italic>\u2009=\u20090.002) and inhibin B (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) levels decreased significantly with 6\u00a0months of CYC therapy. Ovarian volume also reduced significantly (<jats:italic>p<\/jats:italic>\u2009=\u20090.005) with 6\u00a0months of CYC therapy, while antral follicular count reduced numerically (<jats:italic>p<\/jats:italic>\u2009=\u20090.32). Levels of AMH, inhibin-B, estradiol, ovarian volume, and antral follicular count after 6\u00a0months therapy were significantly lesser in the CYC group compared to the MMF group, despite being similar before the start of therapy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Ovarian dysfunction with monthly intravenous CYC (modified NIH regimen) was predominantly subclinical, with a negative effect on ovarian reserve. No premature ovarian failure was noted at 1\u00a0year. No ovarian dysfunction occurred in the MMF group, despite having patients with severe background lupus. Use of intravenous CYC for induction may thus not be restricted in young lupus females with incomplete families for fear of gonadotoxicity, especially in life- or organ-threatening situations, where the benefits outweigh this subclinical risk.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13075-020-02292-y","type":"journal-article","created":{"date-parts":[[2020,8,14]],"date-time":"2020-08-14T18:04:05Z","timestamp":1597428245000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Ovarian dysfunction with moderate-dose intravenous cyclophosphamide (modified NIH regimen) and mycophenolate mofetil in young adults with severe lupus: a prospective cohort study"],"prefix":"10.1186","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8821-6652","authenticated-orcid":false,"given":"Shefali Khanna","family":"Sharma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siddharth","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pooja","family":"Bahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pragna","family":"Potturi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish","family":"Rathi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shankar","family":"Naidu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naresh","family":"Sachdeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varun","family":"Dhir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,14]]},"reference":[{"issue":"5","key":"2292_CR1","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1097\/01.md.0000091181.93122.55","volume":"82","author":"R Cervera","year":"2003","unstructured":"Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P, et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore). 2003;82(5):299\u2013308.","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"2292_CR2","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1191\/096120301671376017","volume":"10","author":"K Takada","year":"2001","unstructured":"Takada K, Illei GG, Boumpas DT. Cyclophosphamide for the treatment of systemic lupus erythematosus. Lupus. 2001;10(3):154\u201361 Review.","journal-title":"Lupus."},{"issue":"6","key":"2292_CR3","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/S0190-9622(84)80193-0","volume":"11","author":"AR Ahmed","year":"1984","unstructured":"Ahmed AR, Hombal SM. Cyclophosphamide (Cytoxan). A review on relevant pharmacology and clinical uses. J Am Acad Dermatol. 1984;11(6):1115\u201326.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"2292_CR4","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/ki.2015.318","volume":"89","author":"M Rathi","year":"2016","unstructured":"Rathi M, Goyal A, Jaryal A, Sharma A, Gupta PK, Ramachandran R, et al. Comparison of low-dose intravenous cyclophosphamide with oral mycophenolate mofetil in the treatment of lupus nephritis. Kidney Int. 2016;89(1):235\u201342.","journal-title":"Kidney Int"},{"issue":"9","key":"2292_CR5","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1191\/0961203304lu2012oa","volume":"13","author":"GE Katsifis","year":"2004","unstructured":"Katsifis GE, Tzioufas AG. Ovarian failure in systemic lupus erythematosus patients treated with pulsed intravenous cyclophosphamide. Lupus. 2004;13(9):673\u20138.","journal-title":"Lupus."},{"issue":"22","key":"2292_CR6","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1056\/NEJM197311292892202","volume":"289","author":"GL Warne","year":"1973","unstructured":"Warne GL, Fairley KF, Hobbs JB, Martin FIR. Cyclophosphamide-induced ovarian failure. N Engl J Med. 1973;289(22):1159\u201362.","journal-title":"N Engl J Med"},{"issue":"1","key":"2292_CR7","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1177\/096120339500400103","volume":"4","author":"CL Wang","year":"1995","unstructured":"Wang CL, Wang F, Bosco JJ. Ovarian failure in oral cyclophosphamide treatment for systemic lupus erythematosus. Lupus. 1995;4(1):11\u20134.","journal-title":"Lupus."},{"issue":"10","key":"2292_CR8","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1056\/NEJM198603063141004","volume":"314","author":"HA Austin 3rd","year":"1986","unstructured":"Austin HA 3rd, Klippel JH, Balow JE, le Riche NG, Steinberg AD, Plotz PH, et al. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med. 1986;314(10):614\u20139.","journal-title":"N Engl J Med"},{"issue":"5","key":"2292_CR9","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1002\/1529-0131(199805)41:5<831::AID-ART9>3.0.CO;2-1","volume":"41","author":"CC Mok","year":"1998","unstructured":"Mok CC, Lau CS, Wong RW. Risk factors for ovarian failure in patients with systemic lupus erythematosus receiving cyclophosphamide therapy. Arthritis Rheum. 1998;41(5):831\u20137.","journal-title":"Arthritis Rheum"},{"issue":"3\u20134","key":"2292_CR10","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1111\/j.1600-0897.1992.tb00780.x","volume":"28","author":"P Langevitz","year":"1992","unstructured":"Langevitz P, Klein L, Pras M, Many A. The effect of cyclophosphamide pulses on fertility in patients with lupus nephritis. Am J Reprod Immunol. 1992;28(3\u20134):157\u20138.","journal-title":"Am J Reprod Immunol"},{"issue":"5","key":"2292_CR11","doi-asserted-by":"publisher","first-page":"366","DOI":"10.7326\/0003-4819-119-5-199309010-00003","volume":"119","author":"DT Boumpas","year":"1993","unstructured":"Boumpas DT, Austin HA 3rd, Vaughan EM, Yarboro CH, Klippel JH, Balow JE. Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy. Ann Intern Med. 1993;119(5):366\u20139.","journal-title":"Ann Intern Med"},{"issue":"2","key":"2292_CR12","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1177\/096120339500400205","volume":"4","author":"HM Belmont","year":"1995","unstructured":"Belmont HM, Storch M, Buyon J, Abramson S. New York University\/Hospital for Joint Diseases experience with intravenous cyclophosphamide treatment: efficacy in steroid unresponsive lupus nephritis. Lupus. 1995;4(2):104\u20138.","journal-title":"Lupus."},{"issue":"8","key":"2292_CR13","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1002\/art.10461","volume":"46","author":"FA Houssiau","year":"2002","unstructured":"Houssiau FA, Vasconcelos C, D'Cruz D, Sebastiani GD, Garrido Ed Ede R, Danieli MG, et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum. 2002;46(8):2121\u201331.","journal-title":"Arthritis Rheum"},{"issue":"4","key":"2292_CR14","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1007\/s00296-018-3995-3","volume":"38","author":"S Mehra","year":"2018","unstructured":"Mehra S, Usdadiya JB, Jain VK, Misra DP, Negi VS. Comparing the efficacy of low-dose vs high-dose cyclophosphamide regimen as induction therapy in the treatment of proliferative lupus nephritis: a single centre study. Rheumatol Int. 2018;38(4):557\u201368.","journal-title":"Rheumatol Int"},{"issue":"3","key":"2292_CR15","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1097\/OGX.0000000000000160","volume":"70","author":"O Oktem","year":"2015","unstructured":"Oktem O, Guzel Y, Aksoy S, Aydin E, Urman B. Ovarian function and reproductive outcomes of female patients with systemic lupus erythematosus and the strategies to preserve their fertility. Obstet Gynecol Surv. 2015;70(3):196\u2013210.","journal-title":"Obstet Gynecol Surv"},{"issue":"1","key":"2292_CR16","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1002\/art.37719","volume":"65","author":"CC Mok","year":"2013","unstructured":"Mok CC, Chan PT, To CH. Anti-m\u00fcllerian hormone and ovarian reserve in systemic lupus erythematosus. Arthritis Rheum. 2013;65(1):206\u201310.","journal-title":"Arthritis Rheum"},{"issue":"8","key":"2292_CR17","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1002\/art.34473","volume":"64","author":"M Petri","year":"2012","unstructured":"Petri M, Orbai AM, Alarc\u00f3n GS, Gordon C, Merrill JT, Fortin PR, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64(8):2677\u201386.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"2292_CR18","first-page":"288","volume":"29","author":"DD Gladman","year":"2002","unstructured":"Gladman DD, Iba\u00f1ez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002;29(2):288\u201391.","journal-title":"J Rheumatol"},{"issue":"1","key":"2292_CR19","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.fertnstert.2011.10.031","volume":"97","author":"MP Rosen","year":"2012","unstructured":"Rosen MP, Johnstone E, McCulloch CE, Schuh-Huerta SM, Sternfeld B, Reijo-Pera RA, et al. A characterization of the relationship of ovarian reserve markers with age. Fertil Steril. 2012;97(1):238\u201343.","journal-title":"Fertil Steril"},{"issue":"3","key":"2292_CR20","doi-asserted-by":"publisher","first-page":"108","DOI":"10.4103\/0974-1208.92283","volume":"4","author":"PR Jirge","year":"2011","unstructured":"Jirge PR. Ovarian reserve tests. J Hum Reprod Sci. 2011;4(3):108\u201313.","journal-title":"J Hum Reprod Sci"},{"key":"2292_CR21","doi-asserted-by":"publisher","first-page":"3785","DOI":"10.1210\/jc.2013-1235","volume":"98","author":"N Morel","year":"2013","unstructured":"Morel N, Bachelot A, Chakhtoura Z, Ghillani-Dalbin P, Amoura Z, Galicier L, et al. Study of anti-Mullerian hormone and its relation to the subsequent probability of pregnancy in 112 patients with systemic lupus erythematosus, exposed or not to cyclophosphamide. J Clin Endocrinol Metab. 2013;98:3785\u201392.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2292_CR22","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1111\/aji.12249","volume":"72","author":"P Ulug","year":"2014","unstructured":"Ulug P, Oner G, Kasap B, Akbas EM, Ozcicek F. Evaluation of ovarian reserve tests in women with systemic lupus erythematosus. Am J Reprod Immunol. 2014;72(1):85\u20138.","journal-title":"Am J Reprod Immunol"},{"issue":"12","key":"2292_CR23","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1089\/jwh.2013.4255","volume":"22","author":"W Ma","year":"2013","unstructured":"Ma W, Zhan Z, Liang X, Chen J, Huang X, Liao C. Subclinical impairment of ovarian reserve in systemic lupus erythematosus patients with normal menstruation not using alkylating therapy. J Women's Health (Larchmt). 2013;22(12):1023\u20137.","journal-title":"J Women's Health (Larchmt)"},{"issue":"6","key":"2292_CR24","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1002\/art.40079","volume":"69","author":"F Tamirou","year":"2017","unstructured":"Tamirou F, Husson SN, Gruson D, Debi\u00e8ve F, Lauwerys BR, Houssiau FA. Brief report: the euro-lupus low-dose intravenous cyclophosphamide regimen does not impact the ovarian reserve, as measured by serum levels of anti-M\u00fcllerian hormone. Arthritis Rheumatol. 2017;69(6):1267\u201371.","journal-title":"Arthritis Rheumatol"},{"key":"2292_CR25","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s00296-007-0478-3","volume":"28","author":"S Appenzeller","year":"2008","unstructured":"Appenzeller S, Blatyta PF, Costallat LTL. Ovarian failure in SLE patients using pulse cyclophosphamide: comparison of different regimens. Rheumatol Int. 2008;28:567\u201371.","journal-title":"Rheumatol Int"},{"key":"2292_CR26","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1191\/0961203304lu1063oa","volume":"13","author":"MC Park","year":"2004","unstructured":"Park MC, Park YB, Jung SY, Chung IH, Choi KH, Lee SK. Risk of ovarian failure and pregnancy outcome in patients with lupus nephritis treated with intravenous cyclophosphamide pulse therapy. Lupus. 2004;13:569\u201374.","journal-title":"Lupus."},{"issue":"3","key":"2292_CR27","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1177\/0961203315598246","volume":"25","author":"AA Gasparin","year":"2016","unstructured":"Gasparin AA, Souza L, Siebert M, Xavier RM, Chakr RMS, Palominos PE, et al. Assessment of anti-M\u00fcllerian hormone levels in premenopausal patients with systemic lupus erythematosus. Lupus. 2016;25(3):227\u201332.","journal-title":"Lupus."},{"issue":"3","key":"2292_CR28","volume":"3","author":"H Chen","year":"2019","unstructured":"Chen H, Xiao L, Li J, Cui L, Huang W. Adjuvant gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in premenopausal women. Cochrane Database Syst Rev. 2019;3(3):CD008018.","journal-title":"Cochrane Database Syst Rev"},{"key":"2292_CR29","unstructured":"Kado R, McCune WJ. Ovarian protection with gonadotropin-releasing hormone agonists during cyclophosphamide therapy in systemic lupus erythematosus. Best Pract Res Clin Obstet Gynaecol. 2019;S1521\u20136934(19)30165\u20138."}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-020-02292-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-020-02292-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-020-02292-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,13]],"date-time":"2021-08-13T23:18:57Z","timestamp":1628896737000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-020-02292-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,14]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["2292"],"URL":"https:\/\/doi.org\/10.1186\/s13075-020-02292-y","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,14]]},"assertion":[{"value":"24 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the Institutional Ethics Committee, Postgraduate Institute of Medical Education and Research, Chandigarh, India (Ref No. INT\/IEC\/2016\/2632).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Taken","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"189"}}